Privileged Structural Motif Detection and Analysis Using Generative Topographic Maps
暂无分享,去创建一个
Jürgen Bajorath | Alexandre Varnek | Dragos Horvath | Michael Gütschow | Shilva Kayastha | Erik Gilberg | J. Bajorath | D. Horvath | S. Kayastha | Erik Gilberg | M. Gütschow | A. Varnek
[1] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[2] D. Hawkins,et al. Analysis of a 2(9) full factorial chemical library. , 1995, Journal of medicinal chemistry.
[3] Pat Langley,et al. Estimating Continuous Distributions in Bayesian Classifiers , 1995, UAI.
[4] Christopher M. Bishop,et al. GTM: The Generative Topographic Mapping , 1998, Neural Computation.
[5] S. Young,et al. Analysis of a Large Structure/Biological Activity Data Set Using Recursive Partitioning. , 2000 .
[6] M. Zhang,et al. The crystal structures of human α‐thrombin complexed with active site‐directed diamino benzo[b] thiophene derivatives: A binding mode for a structurally novel class of inhibitors , 2008, Protein science : a publication of the Protein Society.
[7] S. Loening,et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model , 2002, Oncogene.
[8] J. Adams. Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? , 2003, Biochemistry.
[9] Alison R. Gregro,et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). , 2004, Journal of medicinal chemistry.
[10] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[11] T. I. Richardson,et al. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. , 2004, Journal of medicinal chemistry.
[12] K. O'Byrne,et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. R. Somoza,et al. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. , 2005, Journal of medicinal chemistry.
[14] J. Irwin,et al. ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .
[15] W. Greenlee,et al. Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas. , 2006, Journal of medicinal chemistry.
[16] Cathy H. Wu,et al. The Universal Protein Resource (UniProt): an expanding universe of protein information , 2005, Nucleic Acids Res..
[17] C. Varaprasad,et al. Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[18] B. Cravatt,et al. Metalloprotease Inhibitors GM6001 and TAPI-0 Inhibit the Obligate Intracellular Human Pathogen Chlamydia trachomatis by Targeting Peptide Deformylase of the Bacterium* , 2006, Journal of Biological Chemistry.
[19] D. Fourches,et al. Successful “In Silico” Design of New Efficient Uranyl Binders , 2007 .
[20] Andreas Christmann,et al. Support vector machines , 2008, Data Mining and Knowledge Discovery Handbook.
[21] I. Tetko,et al. ISIDA - Platform for Virtual Screening Based on Fragment and Pharmacophoric Descriptors , 2008 .
[22] J. Wikberg,et al. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction , 2008, Nature Reviews Drug Discovery.
[23] W. Metzler,et al. Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation , 2008, Protein science : a publication of the Protein Society.
[24] P. Clark,et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.
[25] K. Shokat,et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.
[26] Heather B. Miller,et al. Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. , 2008, Bioorganic & medicinal chemistry letters.
[27] Thorsten Meinl,et al. KNIME - the Konstanz information miner: version 2.0 and beyond , 2009, SKDD.
[28] F. Fleming,et al. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.
[29] D. Horvath,et al. ISIDA Property‐Labelled Fragment Descriptors , 2010, Molecular informatics.
[30] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[31] Gilles Marcou,et al. Local neighborhood behavior in a combinatorial library context , 2011, J. Comput. Aided Mol. Des..
[32] J. Christensen,et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.
[33] Héléna A. Gaspar,et al. Generative Topographic Mapping (GTM): Universal Tool for Data Visualization, Structure‐Activity Modeling and Dataset Comparison , 2012, Molecular informatics.
[34] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[35] Alban Arrault,et al. Generative Topographic Mapping-Based Classification Models and Their Applicability Domain: Application to the Biopharmaceutics Drug Disposition Classification System (BDDCS) , 2013, J. Chem. Inf. Model..
[36] M. Radi,et al. Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant. , 2013, Journal of medicinal chemistry.
[37] Olivier Barré,et al. Cleavage Specificity Analysis of Six Type II Transmembrane Serine Proteases (TTSPs) Using PICS with Proteome-Derived Peptide Libraries , 2014, PloS one.
[38] L. Juillerat-Jeanneret. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? , 2014, Journal of medicinal chemistry.
[39] R. Vandenbroucke,et al. Is there new hope for therapeutic matrix metalloproteinase inhibition? , 2014, Nature Reviews Drug Discovery.
[40] Gilles Marcou,et al. An Evolutionary Optimizer of libsvm Models , 2014 .
[41] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[42] Igor I. Baskin,et al. Stargate GTM: Bridging Descriptor and Activity Spaces , 2015, J. Chem. Inf. Model..
[43] Dragos Horvath,et al. Mappability of drug-like space: towards a polypharmacologically competent map of drug-relevant compounds , 2015, Journal of Computer-Aided Molecular Design.
[44] Héléna A. Gaspar,et al. GTM‐Based QSAR Models and Their Applicability Domains , 2015, Molecular informatics.
[45] Andreas Holzinger,et al. Data Mining with Decision Trees: Theory and Applications , 2015, Online Inf. Rev..
[46] Gilles Marcou,et al. Chemical Space Mapping and Structure-Activity Analysis of the ChEMBL Antiviral Compound Set , 2016, J. Chem. Inf. Model..